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Significant contribution of genomic rearrangements in SLC3A1
and SLC7A9 to the etiology of cystinuria.
Background. Cystinuria is an inherited disorder of defective
renal reabsorption of cystine and the dibasic amino acids. Re-
cently, SLC3A1 and SLC7A9 have been identified as responsi-
ble genes. While point mutations in the two genes are well
known to cause cystinuria, only a few studies are aimed on the
identification of gross genomic alterations. Here, we report our
results of a systematic screening for deletions and duplications
in SLC3A1 and SLC7A9 by quantitative real-time polymerase
chain reaction (PCR).
Methods. We screened a cohort of 49 cystinurics for copy
number deviations in the genes SLC3A1 and SLC7A9 by quan-
titative real-time PCR assays using fluorogenic 5 nuclease
chemistry. The detected duplication in SLC3A1 was analyzed
in detail by further real-time assays, reverse transcription (RT)-
PCR and direct sequencing.
Results. In seven patients, we could identify a large duplica-
tion in SLC3A1 spanning from intron 4 to intron 9. This tandem
duplication was accompanied by a small inversion of 25 bp and
a 2 bp deletion in intron 9. As a formation mechanism, we
presume that the inversion in intron 9 and several Alu se-
quences neighbored to the affected region provoke a chromatin
structure that stimulates the duplication event. In addition to
the SLC3A1 duplication, we observed deletions in SLC7A9 in
three patients.
Conclusion. The frequency of genomic rearrangements in
our patient population illustrates the significant contribution
of large genomic alterations to the mutation spectrum in cysti-
nuria. As we could show, quantitative real-time PCR is a reli-
able and effective tool for the identification of unbalanced
genomic rearrangements.
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Cystinuria [MIM 220100] is a common heritable disor-
der of renal reabsorption of cystine and the dibasic amino
acids [1]. It is caused by the defective transport of cystine,
arginine, lysine, and ornithine in the brush-border epi-
thelial cells of the proximal renal tubule and the intesti-
nal tract. The transport is mediated by the rBAT/b0,AT
transporter, the subunits of which are encoded by the
genes SLC3A1 and SLC7A9 [2, 3].
Until recently, the classification of cystinuria in types
I to III was based on the biochemical determination of
urinary cystine hyperexcretion in the patients’ parents
[1, 4]. With the identification of disease-causing genes,
a classification by molecular genetic testing became pos-
sible. While mutations in SLC3A1 are responsible for
type I cystinuria, genomic variations in SLC7A9 are
mainly associated with nontype I. However, mutations
in SLC7A9 are associated with a broad range of cystine
excretion. Up to 14% of heterozygous carriers of muta-
tions in SLC7A9 show normal urinary cystine patterns,
thereby mimicking a type I cystinuria [5]. On the other
hand, 13% of heterozygous carriers develop kidney
stones due to a high level of urinary cystine [6].
So far, more than 70 mutations in SLC3A1 and approxi-
mately 30 alterations in SLC7A9 have been described (for
review, see [5, 7]). The majority of these variants consists
of base pair mutations and was detected in the coding
regions of both genes, while there are only rare reports
on larger genomic alterations restricted to SLC3A1. All
five gross alterations in SLC3A1 described so far were
deletions of one or more exons [8–12].
By conventional polymerase chain reaction (PCR)-
based screening methods, mutations in SLC3A1 and
SLC7A9 can be detected in 57% to 94% of cystinuria
patients (for review, see [7]). This varying detection rate
is mainly influenced by (1) the screening methods used,
(2) the ethnic background of the patients, (3) the bio-
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Fig. 1. Seven fragments in SLC3A1 and five fragments in SLC7A9 were studied. (A ) Duplication detected in our patients in relation to the
organization of the SLC3A1 gene. The baseline represents the genomic structure of SLC3A1. The Alu repeats (MIR, AluSx, and AluJb) possibly
involved in the rearrangement appear as black vertical lines, their orientation is indicated by /. The horizontal black bar indicates the extent
of the novel identified duplication. The localization of fragments used in the fluorogenic 5 nuclease assays are represented by the lower arrows.
Arrows Z, A, B, D, and F symbolize the fragments analyzed by the SYBR green assays. (B ) The minimal extent of deletions in SLC7A9 detected
in our cystinuric patients is shown by the black horizontal bars. Interrupted boxes indicate that the extent of the deletions is unknown. Gray boxes
show the exons and arrows indicate the position of primers and probes used for the quantitative analysis.
chemical classification of patients, and (4) the fact that
the majority of studies focused on mutations within the
coding regions and the intron-exon boundaries.
To elucidate the contribution of large genomic alter-
ations in SLC3A1 and SLC7A9 to the cystinuria pheno-
type, we decided to analyze the two cystinuria genes by
real-time PCR quantification of distinct gene fragments.
We identified a large duplication spanning from intron
4 to intron 9 of SLC3A1 in seven unrelated cystinurics
as well as deletions in SLC7A9 in three patients. To
better understand the mechanism by which the re-
arrangement in SLC3A1 had occurred, we characterized
this alteration in detail.
STUDY POPULATION
Our study population consisted of 49 unrelated cysti-
nuria patients of different ethnic background. The appro-
priate informed consent was obtained from all patients
and their families participating in this study. Patients and
their relatives were named Cys 1 to Cys 112 in order of
their arrival. Results of screening for single base pair
variations in SLC3A1 and SLC7A9 in these patients
have been described previously [7, 13, 14]. As controls,
we used 50 healthy German subjects.
Genomic DNA from patients and controls was ex-
tracted from peripheral lymphocytes using a simple salt-
ing out procedure [15]. DNA samples were diluted in
water to a concentration of 20 ng/L and stored at room
temperature overnight before use.
Some DNA samples were purified by phenol-chloro-
form extraction to exclude impurities influencing the
real-time PCR assays.
METHODS
Quantification by real-time PCR based on fluorogenic
5 nuclease chemistry
For detection of fragment copy number deviations in
SLC3A1 and SLC7A9, we developed quantitative real-
time PCR assays based on 5 nuclease chemistry [16].
We chose seven fragments (exons 1, 4, 5, 6, 7, 8, and 10)
in SLC3A1 and five in SLC7A9 (exons 1, 4, 9, 10, and
13) equally distributed over the two genes (Fig. 1).
To determine the copy number of the test fragments
in SLC3A1 and SLC7A9 and to exclude the influence
of imprecise amounts and qualities of genomic DNA,
we quantified an external reference fragment in parallel.
As reference locus, we used exon 3 of the factor VIII
gene located on the X chromosome [17].
Primers and fluorogenic probes were designed using
the Primer ExpressTM software, version 2.0.0 (Applied
Biosystems, Weiterstadt, Germany). For the test frag-
ments, 6-carboxy-fluoresceine (FAM) reporter dyes
were connected to the 5 end of the probes, the reference
probe factor VIII contained a VICTM reporter dye
[17]. As quencher dye, 6-carboxy-tetramethylrhodamine
(TAMRA) was connected to the 3 end of all probes.
Sequences of primers and probes are listed in Table 1.
Primers were purchased from MWG (Ebersberg, Ger-
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Table 1. Sequences of primers and fluorogenic probes used for real-time quantification of the different fragments
Fragment Primer sequence 5→3 Nucleotide positionb Probe sequence 5→3 Nucleotide positionb
Factor VIIIa F: ctaccatccaggctgaggtttatg acagtggtcattacacttaagaacatggcttccc
R: caccaacagcatgaagactgaca
SLC3A1 exon 1 F: gcttctgtgctggtgctcatc 2203933-2203953 cggccaccatagccatcattgcc 2203955-2203977
R: accagtctaggcactttggagaga 2203979-2204002
SLC3A1 exon 4 F: cagtttatgaaagagcaacctgattt 2214210-2214235 aatttccgcaatcctgatgttcaagaagaaa 2214237-2214267
R: aatggagaagtctgtgtgggtatct 2214281-2214305
SLC3A1 exon 5 F: tctggctcacaaagggtgttg 2228099-2228119 tggttttagtttggatgctgttaaattcctcctaga 2228121-2228156
R: tctcatctctcaggtgctttgc 2228158-2228179
SLC3A1 exon 6 F: tgtcgtcctggttttcaaagg 2229098-2229118 caatactcggagctgtac 2229130-2229147
R: ctgcgtggtggtgaagtcat 2229149-2229168
SLC3A1 exon 7 F: gactgaagcctatgcagagagtattg 2232267-2232291 caggaccgtgatgtactatggattgcca 2232294-2232321
R: agggaaaatcagcttcttggataa 2232323-2232346
SLC3A1 exon 8 F: ttaaaaatatctgcctttcagattgg 2240680-2240705 agacagttcacggctgacttcgcgt 2240712-2240736
R: ttcatcacgttgacatactgattcc 2240741-2240765
SLC3A1 exon 10 F: ggaatgacagccactatgttgtg 2248417-2248439 acacaagagagctggatggcatcgaca 2248441-2248467
R: ccaaaattcagaaccacgataaaga 2248471-2248495
SLC7A9 exon 1 F: ctctgtaccttctggacttcctttg 26829-26853 tcctgggcacaagacatggcca 26855-26876
R: tgcacggtccaaccctaga 26879-26897
SLC7A9 exon 4 F: tggcacaatgatcaccaagtc 32324-32344 ccgcctacctcttctcctgggcc 32389-32411
R: cgtgggcttaatgacgatcag 32415-32435
SLC7A9 exon 9 F: cgttccactttttgtggcatt 38135-38155 caaccatcggtgctgctaacgggac 38158-38182
R: ctgcccgctgtgaagca 38184-38200
SLC7A9 exon 10 F: tggcctcccaaggtgttg 52434-52451 attacaggcgtgagccaccacacctagt 52454-52481
R: tgaggaggttaaacgcactgaga 52483-52505
SLC7A9 exon 13 F: caccttcagatgctaatggaagtg 65971-65994 tcccaccggaggaagaccctgag 65996-66018
R: ttggctacaagagacggagctt 66023-66044
a See reference [17]
b Nucleotide position corresponding to GI 27480191 for SLC3A1 and GI 16195192 for SLC7A9
many) and Operon (Hilden, Germany) and probes were
supplied by Applied Biosystems, Operon, and Sigma
(Darmstadt, Germany).
Real-time PCR was carried out using the ABI PRISM
7000 sequence detection system, 96-well optical reaction
plates, and optical adhesive covers (Applied Biosys-
tems). Reaction conditions corresponded to that de-
scribed recently [18].
Data evaluation was carried out using the ABI PRISM
7000 sequence detection software according to Wilke et
al [17]. The DNA concentrations of target and reference
locus were quantified using standard curves created for
each fragment. We calculated the ratios of test and refer-
ence fragments to determine the copy numbers of the
test fragments. Since the reference gene factor VIII is
located on the X chromosome and the DNA sample of
a healthy female individual was used as standard in all
amplifications, the ratio of male individuals had to be
divided by two. The ratio was expected to be 1 in
individuals with two copies, whereas a ratio of 0.5
should correspond to one copy. Patients with three and
four copies should show a ratio of 1.5 and 2, respec-
tively.
For exclusion of genomic rearrangements to be poly-
morphisms in the general population, we additionally
tested DNA from 50 healthy controls with the assays for
exon 6 of SLC3A1 and exon 1 of SLC7A9.
Table 2. Primers used for narrowing down the duplicated region
in SLC3A1 by SYBR green quantitative assays
Fragment Primer sequence Nucleotide positiona
SLC3A1-YAR R: ttacacactcaaaaggggtg 2216074-2216093
SLC3A1-Z F: tctactttctatcttttacccacctaagc 2216554-2216576
R: cagacacctaccagggatatacagatac 2216631-2216658
SLC3A1-A F: gacctttggcatgaaggagact 2219721-2219742
R: cctgcttaactctattgcagaaacaa 2219780-2219805
SLC3A1-B F: tgtagttccagggcttgcctaa 2224473-2224394
R: gtgcctttatcttttaccaaattcattc 2224530-2224561
SLC3A1-D F: ggcttgtccagaacgtactgaaa 2244543-2244565
R: acggaattctgtatctatcttccatgt 2244603-2244629
SLC3A1-DCF F: gggttcaagtgattctcctg 2246299-2246318
SLC3A1-F F: cccaaatcatctttaatgaacacatact 2207987-2247731
R: tgcacagctaatagaagacaaagttga 2247802-2247828
a Nucleotide position corresponding to GI 27480191; for localization of the
fragments see Figs. 1A and 2A
Confinement of the duplication in SLC3A1 by SYBR
green real-time assays
After detection of duplications of a genomic region
spanning in minimum from exon 5 to exon 8 in SLC3A1,
we aimed at identifying the genomic sequences in which
the rearrangements occurred. Since Alu sequences are
accounted to cause duplications and deletions by un-
equal crossing overs, we screened the SLC3A1 gene se-
quence for short interspersed nuclear elements (SINEs)
using the UCSC Genome Browser. We detected 16
SINEs in the 5 critical region in intron 4 and five SINEs
in the 3 region in intron 9.
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Fig. 2. Genomic structure of the rearranged
region in SLC3A1 and localization of the
primers used for identification of the junction
fragment. (A ) Like Fig. 1, the baseline repre-
sents the SLC3A1 gene, the AluSx repeats
directly neighbored to the transition site are
indicated by black boxes. Localization and ori-
entation of primers DCF and YAR and cDNA
primers C5D and C3R are represented by thin
arrows. Extent and orientation of the re-
arranged sequences are symbolized by the
arrow(s) below the baseline. (B ) Sequence
analysis of genomic DNA of the rearranged
region including the transition site intron
9/intron 4. (C ) RNA junction sequence identi-
fied by cDNA sequencing showing the transi-
tion from exon 9 to exon 5.
Based on the scanning result, we constructed primers
between the SINEs in the regions of interest (Fig. 1A)
and performed quantitative real-time PCR analyses us-
ing SYBR green. Primers were purchased from MWG
and sequences are listed in Table 2. PCRs were per-
formed on the ABI PRISM 7000 sequence detection
system. Reactions were carried out in a volume of 25 L
using the qPCRTM Core Kit for SYBR Green I ac-
cording to the manufacturer’s protocol (Eurogentec, Se-
raing, Belgium).
All samples were analyzed in triplicate, using 50 ng of
genomic DNA in each reaction. Generation of standard
curves, cycling conditions, and data evaluation corre-
sponds to that described for the fluorogenic 5 nuclease
assays.
Verification of a junction fragment in SLC3A1
If the duplication in SLC3A1 in the patients was a
tail-to-head duplication, one should be able to amplify
a junction fragment that includes the transition site be-
tween introns 9 and 4 in patients’ DNA. Therefore, we
performed a PCR with the primers DCF/YAR (Table 2)
(Fig. 2A), including the transition site. The PCR products
were sequenced using the ABI PRISM BigDyeTM Ter-
minator Cycle Sequencing Ready Reaction Kit, version
2.0 (Applied Biosystems) according to standard proto-
cols and samples were applied on an ABI PRISM 377
sequencing system (Applied Biosystems).
To demonstrate the alteration in SLC3A1 on RNA
level, we isolated RNA from two duplication carriers
(Cys 10 and Cys 16) from peripheral lymphocytes using
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Table 3. Reproducibility of the quantification assays, based on at least five independent polymerase chain reactions (PCRs)
for each fragment and for each observed copy number
Gene Exon Expected ratioa Mean measured ratio Range SD CV %
SLC3A1 1 1 0.88 0.81–0.99 0.057 6.5
4 1 0.92 0.85–1.08 0.082 9.01
5 1 0.92 0.86–1.01 0.054 5.82
1.5 1.59 1.34–1.76 0.157 9.89
2 2.17 1.87–2.31 0.128 5.88
6 1 1.0 0.87–1.15 0.098 9.85
1.5 1.52 1.36–1.71 0.151 9.95
2 2.02 1.76–2.24 0.196 9.71
7 1 1.01 0.82–1.16 1.113 11.17
1.5 1.5 1.38–1.67 0.097 6.45
2 2.05 1.82–2.27 0.155 7.58
8 1 0.98 0.86–1.10 0.082 8.37
1.5 1.36 1.25–1.45 0.078 5.71
2 2.05 1.81–2.24 0.152 7.75
10 1 1.03 0.91–1.10 0.070 6.81
SLC7A9 1 0.5 0.5 0.46–0.53 0.029 5.89
1 1.0 0.95–1.09 0.048 4.77
4 0.5 0.52 0.46–0.53 0.061 11.63
1 1.0 0.83–1.2 0.148 14.79
9 0.5 0.5 0.48–0.54 0.021 4.29
1 1.0 0.82–1.18 0.149 14.9
10 0.5 0.48 0.4–0.59 0.065 13.71
1 1.05 0.9–1.17 0.093 8.9
13 0.5 0.51 0.47–0.58 0.04 7.95
1 1.04 0.98–1.12 0.06 5.77
Abbreviations are: SD, standard deviation; CV, coefficient of variation.
a One copy: ratio  0.5 copies; two copies: ratio  1.0; three copies: ratio 1.5; four copies: ratio  2.0
the QIAamp RNA Blood Mini Kit (Qiagen, Hilden,
Germany). cDNA was synthesized using the Reverse
Transcription System (Promega, Madison WI, USA).
cDNA primers C3D and C5R [2] located in exons 2
and 10 were used to generate a fragment, including the
duplicated region. Additionally, cDNA primers C5D and
C3R [2] located in exon 9 and exon 7 (Fig. 2A) were
used to amplify the junction fragment in patients’ cDNA.
This fragment was directly sequenced.
RESULTS
A total of 49 patients suffering from cystinuria were
screened for copy number deviations of SLC3A1 and
SLC7A9 by quantitative real-time PCR. In these pa-
tients, compound or mixed heterozygosity for mutations
in both genes was excluded in previous studies [7, 14].
In 10 patients, variations of fragment copy numbers
could be detected. Seven showed increased values for the
fragments of exons 5, 6, 7, and 8 in SLC3A1, indicating a
duplication of this region. In three patients, copy num-
bers corresponding to a deletion in SLC7A9 could be
demonstrated.
Validation of the real-time PCR assays
Based on the real-time PCR results, the ratios of target
and reference gene were calculated. Patients and con-
trols with ratios ranging from 0.8 to 1.2 were considered
to carry two fragment copies (wild-type). In the case of
one copy, a ratio ranging from 0.4 to 0.6 was determined
(Table 3). In the case of three copies, ratios between 1.25
and 1.75, and in the case of four copies, ratios between 1.8
and 2.5 were obtained, respectively. For DNA samples
revealing deviations from the wild-type copy number,
we performed at least three independent runs for con-
firmation.
To test the reproducibility of each quantitative assay,
we performed at least five independent real-time PCR
reactions for each observed copy number of the respec-
tive fragments (Table 3).
There was no overlap between the mean ratios deter-
mined for the different copy numbers, thereby allowing
an unambiguous differentiation between one, two, three,
and four fragment copies in every DNA sample (Table 3).
The quantification procedure was additionally vali-
dated by analysis of 50 controls for exon 6 of SLC3A1
and exon 1 of SLC7A9. The copy number of all control
samples matched in the range from 0.8 to 1.2 for two
copies. Thereby, we could exclude that the observed
genomic rearrangements were polymorphisms.
Quantification of SLC3A1 fragments
Among the 49 patients, seven showed an increased
copy number of exons 5, 6, 7, and 8 of SLC3A1 in the 5
nuclease assays. Real-time PCR of neighbored fragments
gave normal values (Fig. 1A). In Cys 10, Cys 16, Cys 29,
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Table 4. Genotypes of the patients carrying deletions and duplications in the two cystinuria genesa
Gene Patient Ethnic origin Genotype
SLC3A1 Cys 10 German M467T/duplication exon 5-9
Cys 16 German M467T/duplication exon 5-9
Cys 29 German Duplication exon 5-9/-
Cys 41 German Duplication exon 5-9/duplication exon 5-9
Cys 42 German T216M/duplication exon 5-9
Cys 60 German Duplication exon 5-9/duplication exon 5-9
Cys 87 German Duplication exon 5-9/duplication exon 5-9
SLC7A9 Cys 15 Italian Deletion exon 1-13/-
Cys 51 German c969_971del/deletion exon 1-13
Cys 107 German Deletion exon 1-4/-
a Results on the screening for single basepair mutations had been published recently [7, 13, 14]
and Cys 42, three copies could be detected, and in Cys
41, Cys 60, and Cys 87, four copies of these exons could
be detected (Table 4).
To rule out that DNA impurities cause amplification
interferences, we purified the DNA samples of patients
carrying three or four copies by phenol-chloroform ex-
traction. The possibility that DNA quality and mutations
in the reference gene lead to false positive results was
excluded by determination of the copy number of the
growth hormone GH1 gene using a test established pre-
viously [19]. In this approach, normal copy numbers were
obtained.
After detection of duplications in SLC3A1, we aimed
at identifying the genomic sequences in which the re-
arrangements occurred. By quantitative real-time PCR
analyses using SYBR green, we could narrow down the
duplicated region between fragments D in intron 9 and
Z in intron 4 (Fig. 1A).
Analysis by PCR with primers DCF/YAR (Table 2)
(Fig. 2A) on genomic DNA level allowed the identifica-
tion of a junction fragment that included the transition
site between introns 9 and 4 in patients’ DNA. This
fragment of approximately 700 bp was detectable only
in patients’ DNA samples, not in controls. By direct
sequencing of the PCR product, we could identify the
duplication breakpoints in introns 9 and 4 (Fig. 2B).
Intron 9 ended at nt 2246715 (nucleotide position corre-
sponds to that in GenBank GI 27480191), followed by
a short inversion of the subsequent intron 9 sequence
(nt 2246742-2246718) with a deletion of two base pairs
(nt 2246716 and nt 2246717). Because of the sequence
identity of the following five base pairs with the first
nucleotides of the rearranged fragment of intron 4, we
could not elucidate whether they belonged to intron 9
or intron 4. The sequence of intron 4 unambiguously
started at position 2215804.
The duplication could also be confirmed on RNA level
in two cystinuric patients. PCR with the exonic primers
C3D/C5R [2] yielded two products in patients’ cDNA:
a product corresponding to the wild-type allele with a
length of approximately 1100 bp and a product including
the duplication with a length of nearly 1500 bp. As ex-
pected, in controls only the 1100 bp allele was visible
(data not shown).
Additionally, amplification with cDNA primers C5D
and C3R [2] on cDNA level yielded a PCR product
corresponding to a junction fragment with a tail-to-head
orientation of the duplicated region (Fig. 2A); direct
sequencing confirmed the finding obtained from genomic
DNA analysis. Exon 9 was directly followed by exon 5
(Fig. 2C).
Phenotypically, all seven carriers of the duplication in
the SLC3A1 gene showed a classical cystinuria (i.e., they
suffered from recurrent renal cystine stones and elevated
urine cystine levels) [7, 14]. Interestingly, all these pa-
tients were of German origin.
In case of two patients with four fragment copies (Cys
60 and Cys 87), one parent was available each. These
parents were typed biochemically to be type I carriers
[7]; in each parent, three SLC3A1 copies could be shown.
In case of Cys 29, the affected brother (Cys 30) and
the nonaffected father (Cys 31) also bore three copies.
An overview on all mutations detected in these pa-
tients, including those variants published recently [7, 14],
is given in Table 4.
Quantification of SLC7A9 fragments
By the 5 nuclease assays for SLC7A9 fragments, we
detected deletions in three patients (Table 4) (Fig. 1B).
The deletion in case Cys 107 spanned from exon 1 to
exon 4 and could also be detected in the patient’s affected
sister. The sibpair was of German origin. Both sisters
developed stones at the age of 10 and 5 years, respec-
tively. The cystine and dibasic amino acid values corre-
sponded to a classical cystinuria [7].
Two further patients (Cys 15 and Cys 51) carried dele-
tions encompassing at least the whole coding SLC7A9
sequence from exon 1 to exon 13 (Fig. 1B). These pa-
tients were of Italian and German origin, respectively.
Both patients suffered from recurrent stone formation.
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Table 5. Frequencies of point mutations and gross rearrangements
in the two cystinuria genes observed in our cohort of patients,
including those published previously [7, 14]a
Gene Type of mutation Chromosomes (N  116)
SLC3A1 Point mutations 37.9% (44)
Duplications 8.6% (10)
SLC7A9 Point mutations 15.5% (18)
Deletions 2.6% (3)
Total 64.7% (75)
a The total number of chromosomes is given in parentheses
DISCUSSION
More than 70 mutations in SLC3A1 and approxi-
mately 30 mutations in SLC7A9 in cystinuria patients
have been reported to date. Out of these, only five were
gross rearrangements in SLC3A1 [8–12], while there are
no reports on large deletions or duplications in SLC7A9.
This lack of data concerning large genomic alterations
is in part due to the difficulty to detect duplications or
deletions by conventional PCR-based screening methods
such as (RNA-) single-strand conformational polymor-
phism (SSCP) or direct sequencing. This is the first report
on a systematic screening for copy number variations
in SLC3A1 and SLC7A9. Ten of our patients showed
mutations affecting large genomic regions. Seven pa-
tients carried a large duplication in the SLC3A1 gene,
three patients bore deletions in the SLC7A9 gene. In
previous studies, we analyzed a total cohort of 59 cysti-
nuric patients. Out of these, 10 were carriers of com-
pound or mixed heterozygosity for mutations in SLC3A1
and/or SLC7A9 [7, 14]. With a frequency of 10 out of
the remaining 49 patients, we could show that duplica-
tions and deletions in these genes significantly contribute
to the mutation spectrum in cystinuria (Table 5).
The uncommon complex genomic rearrangement in
SLC3A1 consisted of a duplication spanning from intron
4 to intron 9. While the extent of the deletions published
so far in SLC3A1 is different and seems to be unique
for each patient, the duplication observed in our study
population is identical in the seven patients; they were
unrelated, but of German origin. So far, we have screened
only 23 non-German and 26 German patients. Further
analysis in larger cohorts of patients from other countries
will be necessary to investigate the possibility of a Ger-
man founder.
In close neighborhood to both affected regions in in-
trons 4 and 9 of SLC3A1, three different Alu repeats,
MIR, AluSx, and AluJb, are localized (Fig. 1A). Out of
these, the AluSx and AluJb elements have an identity
of more than 76%. Due to this content of repetitive
DNA elements, the affected regions might be prone to
recombination as reported for other diseases (for review,
see [20]). Uncommonly, the duplication in our patients
was accompanied by a small inversion of 25 bp and a
two base pair deletion in intron 9. In most disorders,
inversions are rare findings, but both large and small
inversions have been described (for review, see [21]).
Rohrer et al [21] described an inversion in the Btk gene,
which was thought to be mediated by Alu repeats. Based
on this knowledge, we propose the following formation
mechanism of the complex rearrangement (Fig. 3). Ini-
tially, the inversion in intron 9 was mediated by a loop
formation due to small complementary sequences in the
same DNA strand. This process was accompanied by a
two base pair deletion. The subsequent duplication might
have been mediated by an unequal crossing over be-
tween small homologous regions in introns 9 and 4. Ac-
cording to this model, the inversion event provokes a
chromatin structure that predisposes the rearranged
structure for recombination. The different Alu elements
neighbored to the transition site might play a role in
bringing both regions closer to each other.
The duplicated region in SLC3A1 ranges from exon
5 to exon 9 and does not shift the reading frame. In the
protein, the duplication affects the extracellular domain
of the heavy subunit of the renal rBAT/b0,AT trans-
porter. This region includes the glycosidase-like extracel-
lular domain that is thought to be necessary for the
transport properties of the transporter and the intracellu-
lar trafficking of rBAT. Most point mutations described
and analyzed in this region affect trafficking of the rBAT
protein in the membrane (for review, see [22]). The du-
plication does not affect the cysteine residue (C117) that
is involved in the disulfide link between rBAT and
b0,AT. However, we can only speculate on the effect
of the mutation due to the limited knowledge of the
rBAT protein structure.
In addition to the duplication in SLC3A1, three of our
patients were carriers of a deletion in SLC7A9 (Table
4). Two of the deletions in SLC7A9 span the whole gene
(Fig. 1B), thereby causing a haploinsufficiency of b0,AT.
In the case of patient Cys 107, the deletion encompasses
at least exons 1 to 4 (Fig. 1B) (i.e., the transcription start
is missing). Thus, the functional consequence should be
the same as postulated for the deletions of the whole
gene.
All carriers of gross genomic alterations in the two
genes described here show a classical cystinuria charac-
terized by recurrent stone formation, as reported for
all patients homozygous or compound heterozygous for
mutations in SLC3A1 and SLC7A9.
Altogether, the deletions and duplications in SLC3A1
and SLC7A9 identified in this study account for 11.2%
of all mutations detected in SLC3A1 and SLC7A9 in
our laboratory (Table 5); the remaining mutations are
single base pair substitutions or small deletions that are
detectable by SSCP analysis. Therefore, we could in-
crease our detection rate from 53.5% of chromosomes
to 64.2% in our cohort of patients. Since there is no
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Fig. 3. Possible formation mechanism of the
complex rearrangement in SLC3A1. The gray
boxes mark the complementary sequences in
introns 9 and 4, which possibly pair, thereby
allowing the rearrangement.
study reaching a detection rate of 100% for mutation in
the two genes, it had been postulated that promotor
mutations, intronic variants creating or enhancing cryptic
splice sites as well as large genomic rearrangements in
one of the known cystinuria genes, contribute to the
cystinuria phenotype in addition to point mutations.
Now, we can show that gross rearrangements indeed
play a significant role in the etiology of the disease.
Therefore, this type of mutation has to be considered
in screening approaches for mutations in SLC3A1 and
SLC7A9 and is underrepresented in the mutation reports
published so far. As we were able to show, real-time
PCR assays are reliable and effective tools for the identi-
fication of complex genomic rearrangements and are use-
ful as diagnostic tests.
DATABASES
Online Mendelian Inheritance in Man (OMIM), http://
www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?dbOMIM
(for cystinuria [MIM 220100]); UCSC Genome Browser,
http://genome.ucsc.edu; and GenBank, http://www.ncbi.
nlm.nih.gov/Genbank/index.html (for SLC3A1 GI
27480191 and for SLC7A9 GI 16195192).
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